7 studies found for:    22689675 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma
Condition: Multiple Myeloma
Interventions: Drug: M-VTD-PACE;   Drug: TT3-LITE Regimen (L-TT3)
2 Completed SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma
Condition: Multiple Myeloma
Interventions: Biological: recombinant interferon alfa;   Drug: carmustine;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: melphalan;   Drug: prednisone;   Drug: vincristine sulfate;   Procedure: allogeneic bone marrow transplantation;   Procedure: autologous bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
3 Active, not recruiting TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
Condition: Multiple Myeloma
Interventions: Drug: Thalidomide;   Drug: Ara-C;   Drug: BCNU;   Drug: Cisplatin;   Drug: Cytoxan;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Filgrastim;   Drug: Recombinant GM-CSF;   Drug: Interferon-alpha-2b;   Drug: Melphalan;   Drug: Vincristine
4 Active, not recruiting UARK 2003-33, Total Therapy III
Condition: Multiple Myeloma
Interventions: Drug: Velcade;   Drug: Thalidomide
5 Active, not recruiting Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: lenalidomide;   Drug: bortezomib;   Other: laboratory biomarker analysis
6 Completed D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Thalidomide
7 Active, not recruiting UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib (Velcade);   Drug: Thalidomide;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Etoposide;   Drug: Filgrastim;   Drug: Lenalidomide

Indicates status has not been verified in more than two years